Primary graft dysfunction after lung transplantation.
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
01 06 2023
01 06 2023
Historique:
pmc-release:
01
06
2024
medline:
8
5
2023
pubmed:
14
4
2023
entrez:
13
4
2023
Statut:
ppublish
Résumé
Primary graft dysfunction (PGD) is a clinical syndrome occurring within the first 72 h after lung transplantation and is characterized clinically by progressive hypoxemia and radiographically by patchy alveolar infiltrates. Resulting from ischemia-reperfusion injury, PGD represents a complex interplay between donor and recipient immunologic factors, as well as acute inflammation leading to alveolar cell damage. In the long term, chronic inflammation invoked by PGD can contribute to the development of chronic lung allograft dysfunction, an important cause of late mortality after lung transplant. Recent work has aimed to identify risk factors for PGD, focusing on donor, recipient and technical factors both inherent and potentially modifiable. Although no PGD-specific therapy currently exists, supportive care remains paramount and early initiation of ECMO can improve outcomes in select patients. Initial success with ex-vivo lung perfusion platforms has been observed with respect to decreasing PGD risk and increasing lung transplant volume; however, the impact on survival is not well delineated. This review will summarize the pathogenesis and clinical features of PGD, as well as highlight treatment strategies and emerging technologies to mitigate PGD risk in patients undergoing lung transplantation.
Identifiants
pubmed: 37053083
doi: 10.1097/MOT.0000000000001065
pii: 00075200-202306000-00006
pmc: PMC10214980
mid: NIHMS1896907
doi:
Types de publication
Review
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
180-186Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL155821
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Clausen E, Cantu E. Primary graft dysfunction: what we know. J Thorac Dis 2021; 13:6618–6627.
Suzuki Y, Cantu E, Christie JD. Primary graft dysfunction. Semin Respir Crit Care Med 2013; 34:305–319.
Van Raemdonck D, Hartwig MG, Hertz MI, et al. Report of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: a 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1121–1136.
Capuzzimati M, Hough O, Liu M. Cell death and ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2022; 41:1003–1013.
Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M, Ware LB. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part V: predictors and outcomes. J Heart Lung Transplant 2005; 24:1483–1488.
Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24:1454–1459.
Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1097–1103.
Collins J. Imaging of the chest after lung transplantation. J Thorac Imaging 2002; 17:102–112.
Anderson DC, Glazer HS, Semenkovich JW, et al. Lung transplant edema: chest radiography after lung transplantation--the first 10 days. Radiology 1995; 195:275–281.
Kundu S, Herman SJ, Winton TL. Reperfusion edema after lung transplantation: radiographic manifestations. Radiology 1998; 206:75–80.
Herman SJ, Rappaport DC, Weisbrod GL, et al. Single-lung transplantation: imaging features. Radiology 1989; 170:89–93.
Roesel MJ, Sharma NS, Schroeter A, et al. Primary graft dysfunction: the role of aging in lung ischemia-reperfusion injury. Front Immunol 2022; 13:891564.
Vandervelde CM, Vos R, Vanluyten C, et al. Impact of anastomosis time during lung transplantation on primary graft dysfunction. Am J Transplant 2022; 22:1418–1429.
Lyengar A, Schiazza A, Cantu E 3rd. Ex-vivo lung perfusion therapies: do they add value to organ donation? Curr Opin Organ Transplant 2022; 27:204–210.
Querrey M, Chiu S, Lecuona E, et al. CD11b suppresses TLR activation of nonclassical monocytes to reduce primary graft dysfunction after lung transplantation. J Clin Invest 2022; 132:1–15.
Bharat A, Kuo E, Steward N, et al. Immunological link between primary graft dysfunction and chronic lung allograft rejection. Ann Thorac Surg 2008; 86:189–195.
Kreisel D, Sugimoto S, Tietjens J, et al. Bcl3 prevents acute inflammatory lung injury in mice by restraining emergency granulopoiesis. J Clin Invest 2011; 121:265–276.
Fisher AJ, Donnelly SC, Hirani N, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001; 163:259–265.
Chacon-Alberty L, Kanchi RS, Ye S, et al. Plasma protein biomarkers for primary graft dysfunction after lung transplantation: a single-center cohort analysis. Sci Rep 2022; 12:16137.
Gelman AE, Fisher AJ, Huang HJ, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part III: Mechanisms: a 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1114–1120.
Morrison MI, Pither TL, Fisher AJ. Pathophysiology and classification of primary graft dysfunction after lung transplantation. J Thorac Dis 2017; 9:4084–4097.
Cantu E, Lederer DJ, Meyer K, et al. Gene set enrichment analysis identifies key innate immune pathways in primary graft dysfunction after lung transplantation. Am J Transplant 2013; 13:1898–1904.
Cantu E, Shah RJ, Lin W, et al. Oxidant stress regulatory genetic variation in recipients and donors contributes to risk of primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2015; 149:596–602.
Cantu E, Suzuki Y, Diamond JM, et al. Protein quantitative trait loci analysis identifies genetic variation in the innate immune regulator TOLLIP in post-lung transplant primary graft dysfunction risk. Am J Transplant 2016; 16:833–840.
Machuca TN, Cypel M, Yeung JC, et al. Protein expression profiling predicts graft performance in clinical ex vivo lung perfusion. Ann Surg 2015; 261:591–597.
Diamond JM, Arcasoy S, Kennedy CC, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1104–1113.
Cantu E, Diamond JM, Cevasco M, et al. Contemporary trends in PGD incidence, outcomes, and therapies. J Heart Lung Transplant 2022; 41:1839–1849.
Drolen C, Cantu E, Goldberg HJ, et al. Impact of the elimination of the donation service area on United States lung transplant practices and outcomes at high and low competition centers. Am J Transplant 2020; 20:3631–3638.
Jawitz OK, Raman V, Bryner BS, et al. Center volume and primary graft dysfunction in patients undergoing lung transplantation in the United States: a cohort study. Transpl Int 2021; 34:194–203.
Kreisel D, Krupnick AS, Puri V, et al. Short- and long-term outcomes of 1000 adult lung transplant recipients at a single center. J Thorac Cardiovasc Surg 2011; 141:215–222.
Li D, Weinkauf J, Kapasi A, et al. Baseline lung allograft dysfunction in primary graft dysfunction survivors after lung transplantation. Respir Med 2021; 188:106617.
Armstrong HF, Lederer DJ, Bacchetta M, Bartels MN. Primary graft dysfunction: Long-term physical function outcomes among lung transplant recipients. Heart Lung 2016; 45:544–549.
Cohen DG, Christie JD, Anderson BJ, et al. Cognitive function, mental health, and health-related quality of life after lung transplantation. Ann Am Thorac Soc 2014; 11:522–530.
Christie JD, Sager JS, Kimmel SE, et al. Impact of primary graft failure on outcomes following lung transplantation. Chest 2005; 127:161–165.
Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2020 Annual Data Report: lung. Am J Transplant 2022; 22: (Suppl 2): 438–518.
Dark JH. What's new in pulmonary transplantation: finding the right lung for every patient. J Thorac Cardiovasc Surg 2016; 151:315–316.
Mulligan MJ, Sanchez PG, Evans CF, et al. The use of extended criteria donors decreases one-year survival in high-risk lung recipients: a review of the United Network of Organ Sharing Database. J Thorac Cardiovasc Surg 2016; 152:891–898.
Somers J, Ruttens D, Verleden SE, et al. A decade of extended-criteria lung donors in a single center: was it justified? Transpl Int 2015; 28:170–179.
Atagun Guney P, Uygun Kizmaz Y. Bronchial culture growth from the donor and recipient as predictive factors in the detection of primary graft dysfunction and pneumonia after lung transplant. Exp Clin Transplant 2022; 20:930–936.
Venkata-Subramani M, Nunley DR, Roman J. Donor factors and risk of primary graft dysfunction and mortality post lung transplantation: a proposed conceptual framework. Clin Transplant 2021; 35:e14480.
Cerier E, Manerikar A, Kandula V, et al. Postreperfusion pulmonary artery pressure indicates primary graft dysfunction after lung transplant. Ann Thorac Surg 2022.
Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187:527–534.
Ehrsam JP, Schuurmans MM, Laager M, et al. Recipient comorbidities for prediction of primary graft dysfunction, chronic allograft dysfunction and survival after lung transplantation. Transpl Int 2022; 35:10451.
Liu Y, Liu Y, Su L, Jiang SJ. Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis. PLoS One 2014; 9:e92773.
Kurihara C, Manerikar A, Querrey M, et al. Clinical characteristics and outcomes of patients with COVID-19-associated acute respiratory distress syndrome who underwent lung transplant. JAMA 2022; 327:652–661.
Allen JG, Lee MT, Weiss ES, et al. Preoperative recipient cytokine levels are associated with early lung allograft dysfunction. Ann Thorac Surg 2012; 93:1843–1849.
Niroomand A, Qvarnstrom S, Stenlo M, et al. The role of mechanical ventilation in primary graft dysfunction in the postoperative lung transplant recipient: a single center study and literature review. Acta Anaesthesiol Scand 2022; 66:483–496.
Courtwright A, Cantu E. Evaluation and management of the potential lung donor. Clin Chest Med 2017; 38:751–759.
Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, noninferiority, phase 3 study. Lancet Respir Med 2018; 6:357–367.
Loor G, Huddleston S, Hartwig M, et al. Effect of mode of intraoperative support on primary graft dysfunction after lung transplant. J Thorac Cardiovasc Surg 2022; 164:1351–1361.e4.
Fessler J, Vallee A, Guirimand A, et al. Blood lactate during double-lung transplantation: a predictor of Grade-3 primary graft dysfunction. J Cardiothorac Vasc Anesth 2022; 36:794–804.
Tague LK, Bedair B, Witt C, et al. Lung protective ventilation based on donor size is associated with a lower risk of severe primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2021; 40:1212–1222.
Hartwig MG, Walczak R, Lin SS, Davis RD. Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation. Ann Thorac Surg 2012; 93:366–371.
Takahashi K, Hasegawa S, Maeba S, et al. Serum tau protein level serves as a predictive factor for neurological prognosis in neonatal asphyxia. Brain Dev 2014; 36:670–675.
Loor G. EVLP: ready for prime time? Semin Thorac Cardiovasc Surg 2019; 31:1–6.
Ahmad K, Pluhacek JL, Brown AW. Ex vivo lung perfusion: a review of current and future application in lung transplantation. Pulm Ther 2022; 8:149–165.
Popov AF, Sabashnikov A, Patil NP, et al. Ex vivo lung perfusion: state of the art in lung donor pool expansion. Med Sci Monit Basic Res 2015; 21:9–14.
Cypel M, Yeung JC, Machuca T, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J Thorac Cardiovasc Surg 2012; 144:1200–1206.
Tikkanen JM, Cypel M, Machuca TN, et al. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. J Heart Lung Transplant 2015; 34:547–556.